NCT02815748

The Metabolite Identification and Material Balance Study of SP2086

A Single-center, Randomized, Open, Single Dose Phase I Study to Access the Metabolite Identification and Material Balance in Health Volunteer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to investigate the Metabolite identification and material balance of SP2086 in healthy adult volunteers.

Detailed description

All subjects were given SP2086 100mg only one time, and blood sample should be collected before and 96 hours after medicine taken.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	SP2086	SP2086 was taken only one time at 100mg dose in health volunteers

Timeline

• Start date: 2015-08-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2016-06-28
• Last updated: 2016-07-01